EMA Authorised: Ngenla (somatrogon) — Pfizer Europe MA EEIG

View source ↗

Summary

The European Medicines Agency has authorised Ngenla (somatrogon) from Pfizer Europe MA EEIG for treatment of pediatric growth hormone deficiency, with orphan me…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• NGENLA (SOMATROGON-GHLA)

Snippet

Status: Authorised. Therapeutic area: Growth and Development. MAH: Pfizer Europe MA EEIG. Decision date: 16/12/2025. Orphan medicine